BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Anderson J, Moonie S, Hogan MB, Scherr R, Labus B, Word J. Cost of chronic inflammatory disease: The impact of eosinophilic esophagitis in Nevada. J Dig Dis 2019;21:12-9. [DOI: 10.1111/1751-2980.12832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Tamarit-sebastian S, Ferrer-soler FM, Lucendo AJ. Current options and investigational drugs for the treatment of eosinophilic esophagitis. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2033207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lucendo AJ, Santander C, Savarino E, Guagnozzi D, Pérez-martínez I, Perelló A, Guardiola-arévalo A, Barrio J, Elena Betoré-glaria M, Gutiérrez-junquera C, Ciriza de los Ríos C, Racca F, Fernández-fernández S, Blas-jhon L, Lund Krarup A, de la Riva S, Naves JE, Carrión S, Rodríguez Oballe JA, García-morales N, Tamarit-sebastián S, Navarro P, Arias Á, Laserna-mendieta EJ, Casabona-francés S, Pérez-fernández T, Llerena Castro R, Ghisa M, Manie D, Pellegatta G, Suárez A, Alcedo J, Gil Simón P, Teresa Palomeque M, Asensio T, Granja-navacerrada A, de Mendoza Guena LH, Rodríguez Sánchez A, Masiques Mas L, Dainese R, Feo-ortega S. EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe. Therap Adv Gastroenterol 2022;15:175628482210742. [DOI: 10.1177/17562848221074204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Arias Á, Lucendo AJ. Epidemiology and risk factors for eosinophilic esophagitis: lessons for clinicians. Expert Rev Gastroenterol Hepatol 2020;14:1069-82. [PMID: 32749898 DOI: 10.1080/17474124.2020.1806054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Lucendo AJ. Drug treatment strategies for eosinophilic esophagitis in adults. Expert Opin Pharmacother 2022;:1-14. [PMID: 35379069 DOI: 10.1080/14656566.2022.2060077] [Reference Citation Analysis]
5 Hannan N, McMillan SS, Tiralongo E, Steel A. Treatment Burden for Pediatric Eosinophilic Esophagitis: A Cross-Sectional Survey of Carers. J Pediatr Psychol 2021;46:100-11. [PMID: 33216917 DOI: 10.1093/jpepsy/jsaa095] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Feo-ortega S, Lucendo AJ. Evidence-based treatments for eosinophilic esophagitis: insights for the clinician. Therap Adv Gastroenterol 2022;15:175628482110686. [DOI: 10.1177/17562848211068665] [Reference Citation Analysis]
7 Visaggi P, Ghisa M, Barberio B, Maniero D, Greco E, Savarino V, Black CJ, Ford AC, de Bortoli N, Savarino E. Treatment Trends for Eosinophilic Esophagitis and the Other Eosinophilic Gastrointestinal Diseases: Systematic Review of Clinical Trials. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.05.004] [Reference Citation Analysis]